Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients

Author: Abou-Jaoude M.M.   Ghantous I.   Najm R.   Afif C.   Almawi W.Y.  

Publisher: Elsevier

ISSN: 0041-1345

Source: Transplantation Proceedings, Vol.35, Iss.7, 2003-11, pp. : 2731-2732

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content